share_log

At US$42.94, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

At US$42.94, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?

Integra LifeSciences Holdings Corporation(納斯達克股票代碼:IART)的價格爲42.94美元,值得密切關注嗎?
Simply Wall St ·  01/15 06:02

While Integra LifeSciences Holdings Corporation (NASDAQ:IART) might not have the largest market cap around , it saw a significant share price rise of 26% in the past couple of months on the NASDAQGS. Shareholders may appreciate the recent price jump, but the company still has a way to go before reaching its yearly highs again. As a mid-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Let's examine Integra LifeSciences Holdings's valuation and outlook in more detail to determine if there's still a bargain opportunity.

儘管Integra生命科學控股公司(納斯達克股票代碼:IART)的市值可能不是最大的,但在過去幾個月中,納斯達克股票價格大幅上漲了26%。股東們可能會欣賞最近的價格上漲,但該公司在再次達到年度高點之前還有很長的路要走。作爲分析師報道率高的中型股票,你可以假設該公司前景的任何最近變化都已計入該股。但是,該股票還能以相對便宜的價格交易嗎?讓我們更詳細地研究一下Integra LifeSciences Holdings的估值和前景,以確定是否還有討價還價的機會。

View our latest analysis for Integra LifeSciences Holdings

查看我們對Integra 生命科學控股公司的最新分析

What's The Opportunity In Integra LifeSciences Holdings?

Integra LifeSciences Holdings 的機會是什麼?

Great news for investors – Integra LifeSciences Holdings is still trading at a fairly cheap price. Our valuation model shows that the intrinsic value for the stock is $68.27, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. Although, there may be another chance to buy again in the future. This is because Integra LifeSciences Holdings's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

對投資者來說是個好消息——Integra LifeSciences Holdings的交易價格仍然相當便宜。我們的估值模型顯示,該股票的內在價值爲68.27美元,高於市場目前對公司的估值。這表明存在低價買入的潛在機會。但是,將來可能會有另一次買入的機會。這是因爲Integra LifeSciences Holdings的貝塔值(衡量股價波動的指標)很高,這意味着其價格相對於其他市場的價格走勢將被誇大。如果市場看跌,該公司的股票下跌幅度可能會超過其他市場,這提供了絕佳的買入機會。

What does the future of Integra LifeSciences Holdings look like?

Integra LifeSciences Holdings的未來會是什麼樣?

earnings-and-revenue-growth
NasdaqGS:IART Earnings and Revenue Growth January 15th 2024
NASDAQGS: IART 收益和收入增長 2024 年 1 月 15 日

Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. With profit expected to grow by 87% over the next couple of years, the future seems bright for Integra LifeSciences Holdings. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

當你考慮買入股票時,未來前景是一個重要的方面,特別是如果你是尋求投資組合增長的投資者。以低廉的價格收購一家前景看好的優秀公司永遠是一項不錯的投資,因此,讓我們也來看看公司的未來預期。預計未來幾年利潤將增長87%,Integra LifeSciences Holdings的前景似乎一片光明。看來該股的現金流即將增加,這應該會促進更高的股票估值。

What This Means For You

這對你意味着什麼

Are you a shareholder? Since IART is currently undervalued, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

你是股東嗎?由於IART目前的估值被低估,因此現在可能是增加股票持有量的好時機。隨着樂觀前景的臨近,這種增長似乎尚未完全納入股價。但是,還有其他因素需要考慮,例如資本結構,這可以解釋當前的低估。

Are you a potential investor? If you've been keeping an eye on IART for a while, now might be the time to make a leap. Its buoyant future outlook isn't fully reflected in the current share price yet, which means it's not too late to buy IART. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.

你是潛在的投資者嗎?如果你關注IART已有一段時間了,那麼現在可能是做出飛躍的時候了。其活躍的未來前景尚未完全反映在當前的股價中,這意味着現在購買IART還爲時不晚。但是,在做出任何投資決策之前,請考慮其他因素,例如其管理團隊的往績,以便做出明智的投資決策。

In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. For instance, we've identified 3 warning signs for Integra LifeSciences Holdings (1 makes us a bit uncomfortable) you should be familiar with.

有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。例如,我們已經確定了你應該熟悉的Integra LifeSciences Holdings的3個警告信號(其中一個讓我們有點不舒服)。

If you are no longer interested in Integra LifeSciences Holdings, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

如果您不再對Integra LifeSciences Holdings感興趣,可以使用我們的免費平台查看我們列出的其他50多隻具有高增長潛力的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論